{"entity":{"id":"nct07665684","kind":"trial","name":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","aka":["SONIC"],"tldr":"A phase 1/2 trial in pancreatic cancer, run by University Health Network, Toronto, not yet recruiting.","summary":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07665684 by University Health Network, Toronto, with a registry enrolment figure of 67 participants, started 2026-07 and due to reach its primary completion in 2029-05. Interventions recorded: Samuraciclib + Gemcitabine & Nab-Paclitaxel. Conditions listed: Pancreas Ductal Adenocarcinoma; Pancreas Cancer, Metastatic; Pancreatic Adenocarcinoma Metastatic; Adenosquamous Carcinoma of the Pancreas; Mucinous Adenocarcinoma. Primary outcome: Frequencies of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose level; Percentages of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose level; Frequencies of dose-limiting toxicities reported by dose level. Pancreatic eligibility wording from the registry: \"Known homologous recombination deficient pancreatic cancer, including germline or somatic BRCA1/2 or PALB2 mutations\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07665684","url":"https://clinicaltrials.gov/study/NCT07665684"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac","brca-palb2-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07665684","phase":"1/2","setting":"Phase Ib/II Study of Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","sponsor":"University Health Network, Toronto","enrolled":67,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07665684/","neighbours":{"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}